All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fresh Insight on Ipilimumab's Potential in the Adjuvant Melanoma Setting

March 17th 2015

In an interview with OncLive, Ahmad A. Tarhini, MD, PhD, discussed the benefits and challenges of ipilimumab and other immunotherapies and how they could change the adjuvant treatment paradigm for melanoma.

ASCO Report Says Patient Survival Improves But Costs and Administrative Burden Also Climb

March 17th 2015

Patients with cancer are living longer thanks to new treatments, but the US oncology care system is burdened by growing administrative responsibilities, difficulties obtaining payment, and runaway costs.

Report Calls for Drug Pricing Reforms

March 16th 2015

A new report has called for broad changes in the way drugs are priced in the United States, saying the law of supply and demand is not doing an effective job of bringing the cost of cancer drugs down to a level comparable with other countries.

How to Involve Community Oncologists in Molecular-Based Research-and Expedite Results

March 13th 2015

What if a negative study had been made available through a secure online registry where patients could sign up, with the assistance of their own oncologists?

Challenges in the Treatment of Ovarian and Endometrial Cancers

March 13th 2015

OncLive spoke with Sanaz Memarzadeh, MD, on why ovarian and endometrial cancers are so challenging to treat, and what future research is needed to better understand these diseases.

Hopkins Researcher Describes Evolving Challenges of Targeting PI3K in Breast Cancer

March 12th 2015

Josh D. Lauring, MD, PhD, of Johns Hopkins Medicine, discusses efforts to develop breast cancer therapies by targeting the PI3K pathway.

Wistar-Penn Collaboration Identifies HSP70 as Promising New Target for Melanoma Therapy

March 12th 2015

A 10-year collaboration between scientists at The Wistar Institute and the University of Pennsylvania has recently resulted in the emergence of an exciting new target for cancer therapy, heat shock protein 70, that could be helpful in treating patients with melanoma.

FDA Accepts NDA for New Formulation of Melphalan for Myeloma

March 11th 2015

The FDA has accepted a New Drug Application (NDA) for Captisol-enabled (CE) melphalan for the treatment of patients with multiple myeloma prior to autologous hematopoietic stem cell transplantation (AHCT).

'Next Gen' ACO Designed to Boost Savings, Care Quality

March 11th 2015

The Centers for Medicare & Medicaid Services has announced the launch of a "Next Generation Accountable Care Organization Model," designed to increase savings on healthcare spending while improving medical care.

Role of Stem Cell Transplantation Evolving in Multiple Myeloma

March 11th 2015

OncLive interviewed Ravi Vij, MD, associate professor, Division of Oncology, Section of Bone Marrow Transplantation, Washington University School of Medicine and the Siteman Cancer Center, on what the future holds for stem cell transplantation in multiple myeloma.

Targeting Gastric Cancer: Recent Advances Generate Fresh Hopes After Many Frustrations

March 11th 2015

As we enter an era of unprecedented clinical trial activity in gastric cancer, with thousands of patients enrolled or set to be enrolled in large, randomized phase III trials of novel targeted agents, we may finally be on the path to changing the course of this disease.

OncLive Welcomes MD Anderson Cancer Center to Strategic Alliance Partnership Program

March 10th 2015

OncLive today joins with The University of Texas MD Anderson Cancer Center in a partnership to increase awareness of the latest advances in cancer research, treatment and care through OncLive's Strategic Alliance Partnership program.

Precision Medicine: A Promising Future for Treating Cancer

March 10th 2015

Thomas J. Lynch, MD, director, Yale Cancer Center, Physician-in-Chief, Smilow Cancer Hospital at Yale-New Haven, writes about precision medicine in oncology.

Tivozanib Improves PFS Versus Bevacizumab in NRP-1 Low mCRC

March 10th 2015

Low serum neuropilin-1 may indicate longer progression-free survival with tivozanib compared with bevacizumab as a first-line treatment for patients with metastatic colorectal cancer.

Pacritinib Shows Promise for Spleen Reduction in Myelofibrosis

March 10th 2015

Pacritinib, a JAK2/FLT3 multikinase inhibitor, significantly reduced spleen volume for patients with myeloproliferative neoplasms when compared to non-JAK2 inhibitors.

FDA Approves Dinutuximab for High-Risk Neuroblastoma

March 10th 2015

The FDA has approved dinutuximab in combination with interleukin-2, GM-CSF, and 13-cis-retinoic acid as a frontline therapy for pediatric patients with high-risk neuroblastoma.

Lung Cancer Clinical Trials Could See Boost in Enrollment

March 9th 2015

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.

New Targeted Therapy Strategies on Horizon in NSCLC

March 9th 2015

OncLive sat down with Edward Kim, MD, to learn more about the impact of recent advances in NSCLC and what the future treatment paradigm might look like.

Top Breast Cancer Research Findings for the Past Year

March 9th 2015

A new standard that recommends ovarian function suppression (OFS) therapy as a routine adjuvant treatment option for certain premenopausal women with higher risk, hormone receptor (HR)â€“positive breast cancer emerged as the most far-reaching medical oncology research finding in the field for 2014, according to Debu Tripathy, MD.

Balancing Act: Calculating Adjuvant Treatment Risks in Older Women With Breast Cancer

March 6th 2015

Hyman B. Muss, MD, provides expert insight on adjuvant treatment for older patients with breast cancer.